What were Aarti Drugs Ltd's latest quarterly results?
Aarti Drugs Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: -12.7%
- Revenue Growth YoY: +6.4%
- Operating Margin: 13.0%
Aarti Drugs Ltd: Stock Analysis & Fundamentals
Updated this weekAarti Drugs Ltd (Pharma - API) — fundamental analysis, earnings data, and key metrics. PE: 17.4. ROE: 13.4%. This stock is not currently in the Nifty 500 momentum outperformers list.
Aarti Drugs Ltd Key Facts
What's Happening
👔Promoter stake down 0.9% this quarter
🏛️DII accumulation — stake up 2.1%
Key Numbers
Current Price
₹372
Dividend Yield
0.54%
Market Cap
3.4K Cr
Valuation
N/AOther Top Pharma - API Stocks Beating Nifty 500
Frequently Asked Questions: Aarti Drugs Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Aarti Drugs Ltd's current PE ratio?
Aarti Drugs Ltd's current PE ratio is 17.4x.
- Current PE: 17.4x
- Market Cap: 3.4K Cr
- Dividend Yield: 0.54%
What is Aarti Drugs Ltd's price-to-book ratio?
Aarti Drugs Ltd's price-to-book ratio is 2.2x.
- Price-to-Book (P/B): 2.2x
- Book Value per Share: ₹170
- Current Price: ₹372
Is Aarti Drugs Ltd a fundamentally strong company?
Aarti Drugs Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 12.0%
Is Aarti Drugs Ltd debt free?
Aarti Drugs Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹577 Cr
What is Aarti Drugs Ltd's return on equity (ROE) and ROCE?
Aarti Drugs Ltd's return ratios over recent years
- FY2024: ROCE 15.0%
- FY2025: ROCE 13.0%
- FY2026: ROCE 12.0%
Is Aarti Drugs Ltd's cash flow positive?
Aarti Drugs Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹254 Cr
- Free Cash Flow (FCF): ₹81 Cr
- CFO/PAT Ratio: 130% (strong cash conversion)
What is Aarti Drugs Ltd's dividend yield?
Aarti Drugs Ltd's current dividend yield is 0.54%.
- Dividend Yield: 0.54%
- Current Price: ₹372
Who holds Aarti Drugs Ltd shares — promoters, FII, DII?
Aarti Drugs Ltd's shareholding pattern (Mar 2026)
- Promoters: 55.0%
- FII (Foreign): 1.6%
- DII (Domestic): 10.2%
- Public: 33.2%
Is promoter holding increasing or decreasing in Aarti Drugs Ltd?
Aarti Drugs Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 55.0% (Mar 2026)
- Previous Quarter: 55.0% (Dec 2025)
- Change: 0.00% (stable)
Is Aarti Drugs Ltd a new momentum entry or an established outperformer?
Aarti Drugs Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Aarti Drugs Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Aarti Drugs Ltd may be worth studying
- Cash flow is positive — CFO ₹254 Cr
What is the investment thesis for Aarti Drugs Ltd?
Aarti Drugs Ltd investment thesis summary:
What is the future outlook for Aarti Drugs Ltd?
Aarti Drugs Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.